CN111328282A - 加波沙朵在治疗发作性睡病中的用途 - Google Patents

加波沙朵在治疗发作性睡病中的用途 Download PDF

Info

Publication number
CN111328282A
CN111328282A CN201880072667.9A CN201880072667A CN111328282A CN 111328282 A CN111328282 A CN 111328282A CN 201880072667 A CN201880072667 A CN 201880072667A CN 111328282 A CN111328282 A CN 111328282A
Authority
CN
China
Prior art keywords
hours
gaboxadol
pharmaceutically acceptable
patient
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880072667.9A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CN111328282A publication Critical patent/CN111328282A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880072667.9A 2017-09-12 2018-09-11 加波沙朵在治疗发作性睡病中的用途 Pending CN111328282A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762557412P 2017-09-12 2017-09-12
US62/557,412 2017-09-12
PCT/US2018/050339 WO2019055369A1 (en) 2017-09-12 2018-09-11 USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSIA

Publications (1)

Publication Number Publication Date
CN111328282A true CN111328282A (zh) 2020-06-23

Family

ID=65630168

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880072667.9A Pending CN111328282A (zh) 2017-09-12 2018-09-11 加波沙朵在治疗发作性睡病中的用途

Country Status (10)

Country Link
US (2) US20190076409A1 (enExample)
EP (1) EP3661507A4 (enExample)
JP (1) JP2020533415A (enExample)
KR (1) KR20200053570A (enExample)
CN (1) CN111328282A (enExample)
AU (1) AU2018331326A1 (enExample)
CA (1) CA3075478A1 (enExample)
IL (1) IL272962A (enExample)
MX (1) MX2020002741A (enExample)
WO (1) WO2019055369A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661507A4 (en) * 2017-09-12 2020-11-18 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT NARCOLEPSIA
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2021016006A (es) 2019-06-28 2022-04-07 Univ Copenhagen Tratamiento de trastornos del sistema nervioso central (snc) con perturbaciones del sueño.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
US20250375429A1 (en) 2024-05-29 2025-12-11 Smarter Not Harder, Inc. Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
CN1893942A (zh) * 2003-12-18 2007-01-10 H.隆德贝克有限公司 加波沙朵治疗失眠症的用途
US20140349964A1 (en) * 2011-09-29 2014-11-27 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
CN105073106A (zh) * 2013-03-01 2015-11-18 杰资制药爱尔兰有限公司 γ 羟基丁酸与单羧酸转运蛋白的施用
US20170014392A1 (en) * 2015-07-17 2017-01-19 Ovid Therapeutics Inc. Methods of treating developmental disorders using gaboxadol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022197B1 (pt) * 2013-03-13 2022-06-07 Sk Biopharmaceuticals Co., Ltd. Uso de um composto para o tratamento de cataplexia
WO2017205606A1 (en) * 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
EP3661507A4 (en) * 2017-09-12 2020-11-18 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT NARCOLEPSIA

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1893942A (zh) * 2003-12-18 2007-01-10 H.隆德贝克有限公司 加波沙朵治疗失眠症的用途
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
US20140349964A1 (en) * 2011-09-29 2014-11-27 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
CN105073106A (zh) * 2013-03-01 2015-11-18 杰资制药爱尔兰有限公司 γ 羟基丁酸与单羧酸转运蛋白的施用
US20170014392A1 (en) * 2015-07-17 2017-01-19 Ovid Therapeutics Inc. Methods of treating developmental disorders using gaboxadol

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EMMANUEL MIGNOT ET AL.: "Emerging Therapies in Narcolepsy-Cataplexy", 《SLEEP》 *
JAMES K. WALSH ET AL.: "Slow Wave Sleep Enhancement with Gaboxadol Reduces Daytime Sleepiness During Sleep Restriction", 《SLEEP》 *
JAMIE M. ZEITZER ET AL.: "The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions", 《TRENDS IN PHARMACOLOGICAL SCIENCES》 *

Also Published As

Publication number Publication date
US20190076409A1 (en) 2019-03-14
EP3661507A4 (en) 2020-11-18
MX2020002741A (es) 2020-07-21
AU2018331326A1 (en) 2020-03-19
IL272962A (en) 2020-04-30
EP3661507A1 (en) 2020-06-10
WO2019055369A1 (en) 2019-03-21
US20200222372A1 (en) 2020-07-16
CA3075478A1 (en) 2019-03-21
JP2020533415A (ja) 2020-11-19
KR20200053570A (ko) 2020-05-18

Similar Documents

Publication Publication Date Title
AU2023206140B2 (en) Pulsatile drug delivery system for treating morning akinesia
AU2003225837B2 (en) NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
EP2688557B1 (en) Methods and compositions for treatment of attention deficit disorder
US20200222372A1 (en) Use of gaboxadol in the treatment of narcolepsy
US20080021074A1 (en) Pharmaceutical Compositions and Related Methods of Treatment
JP2019116494A (ja) アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
JP2020529440A (ja) 糖尿病および関連する状態の処置におけるガボキサドールの使用
WO2009018514A1 (en) Dosage form and method of use
CA3040027C (en) Melatonin mini-tablets and method of manufacturing the same
KR20080080094A (ko) 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
HK40031715A (en) Use of gaboxadol in the treatment of narcolepsy
US20220241222A1 (en) Atomoxetine hydrochloride extended release compositions and methods of use
JP2022540917A (ja) 治療的処置のためのガボキサドール含有医薬製剤
JP2023504876A (ja) 薬物組成物、キット及びその応用
CN113423399A (zh) 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031715

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20200623

RJ01 Rejection of invention patent application after publication